Market Overview
The Global Artificial Organs and Bionics Market reached US$ 37.85 billion in 2023 and is expected to reach US$ 77.08 billion by 2031, growing at a CAGR of 9.3% during the forecast period 2024-2031.
Artificial organs are human-made devices or tissues that are implanted or integrated into a person’s body to replace, duplicate, or augment the function of a natural organ. These organs interface with living tissue, allowing patients to regain normal functionality and improve their quality of life. Examples include artificial hearts, kidneys, and limbs, which can restore essential bodily functions or enhance physical capabilities.
Bionics, on the other hand, involves the integration of biological systems with electronic components, often resulting in devices that can interact with the nervous system. Bionic devices include prosthetics that can be controlled by neural signals and implants that restore sensory functions, such as cochlear implants for hearing restoration. These factors have driven the global artificial organs and bionics market expansion.
With the growing investments and the rising funding by the government, there is growing research and development of innovative solutions for artificial organs and bionics. For instance, in 2024, BiVacor, a clinical-stage medical device company based in Australia and California, received an award of US$13 million from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP). The funding will support the company’s Total Artificial Heart (TAH) program and future product enhancements.
Executive Summary
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Increasing number of organ transplants
The increasing number of organ transplants is significantly driving the growth of the global artificial organs and bionics market and is expected to drive throughout the market forecast period. The increasing prevalence of chronic diseases such as diabetes, heart disease, and kidney disorders is a significant factor contributing to the rising incidence of organ failure. This escalation in organ failure cases directly correlates with the growing demand for artificial organs and bionics.
According to U.S. Department of Health & Human Services data in January 2024, in 2023, a total of 46,632 organ transplants were performed in the United States, encompassing both living and deceased donors. This figure represents an 8.7% increase compared to 2022 and a 12.7% increase from 2021, which was notable for being the first year to exceed 40,000 organ transplants. The growth in transplant numbers reflects several important trends and factors within the organ donation and transplantation landscape.
The rising rates of organ failure are increasing the demand for artificial organs as substitutes for traditional transplants. These artificial organs can help fill the void caused by the shortage of available donors, offering life-saving alternatives for patients with severe chronic illnesses.
Regulatory hurdles
Regulatory challenges impose significant obstacles on the artificial organs and bionics sector, affecting the speed and efficiency of product development and entrance. The approval processes for artificial organs and bionic devices are frequently lengthy and complex. Regulatory bodies, such as the FDA in the United States and comparable organizations around the world, need rigorous clinical trials to establish product safety and efficacy before it is commercialized. This can delay the deployment of novel technology and limit patients' timely access to them.
Market Segment Analysis
The global artificial organs and bionics market is segmented based on type, material, fixation type, technology, end-user and region.
Type:
Artificial Organs segment is expected to dominate the artificial organs and bionics market share
The artificial organs segment is expected to dominate the global artificial organs and bionics market. The artificial organs segment will continue to dominate the artificial organs and bionics market, owing to many compelling factors driving demand and growth in this field. The global prevalence of chronic diseases such as heart disease, diabetes, and kidney failure is rising, resulting in an increased risk of organ failure. This tendency creates a considerable need for artificial organs to replace failing natural organs, driving up demand for this segment.
Furthermore, the aging population contributes to an increase in chronic diseases and organ failures among older persons, raising the demand for artificial organ solutions because these people frequently require replacements for deteriorating organs.
Companies are conducting advanced research and development of artificial organs and are introducing new organs to meet the rising demand. For instance, in January 2022, IIT-Kanpur launched the Hridyantra project, aimed at developing an advanced Left Ventricular Assist Device (LVAD) in collaboration with several hospitals. This initiative is particularly significant for patients suffering from end-stage heart failure, a condition where the heart can no longer pump blood effectively, leading to severe health complications.
Market Geographical Share
North America is expected to hold a significant position in the artificial organs and bionics market share
North America holds a substantial position in the global artificial organs and bionics market and is expected to hold most of the market share. The rising number of organ transplants significantly influences the demand for artificial organs. In the U.S., there are over 104,234 people on the national waiting list as of 2023, with a new person added every ten minutes. This urgent need for organ replacements drives the demand for artificial medical devices as alternatives.
The companies are receiving approvals for a wide range of organs and devices that are being developed innovatively. For instance, in March 2022, Edwards Lifesciences received FDA approval for the MITRIS RESILIA valve, a tissue valve replacement designed for the heart's mitral position. This valve is notable for its innovative design and advanced materials, which aim to improve patient outcomes in mitral valve replacement surgeries. Thus, the above are expected to hold the region in the dominant position in the global artificial organs and bionics market.
Asia-Pacific is growing at the fastest pace in the artificial organs and bionics market
The Asia-Pacific (APAC) region is experiencing the fastest growth rate in the artificial organs and bionics market, owing to the rising research and development of innovative artificial organs and bionics, increasing incidence of chronic diseases, and the rising number of organ failures. For instance, according to the National Institute of Health, India experiences 17,000–18,000 solid organ transplants performed every year. This increase in the number of organ failures increases the need for artificial organs solutions for transplantions.
Market Competitive Landscape
The major global players in the artificial organs and bionics market include Abiomed Inc. (Johnson & Johnson Services, Inc.), SynCardia Systems, LLC, Medtronic, Boston Scientific Corporation, Zimmer Biomet., Edwards Lifesciences Corporation., Jarvik Heart, Inc., Cochlear Ltd., Berlin Heart and Ekso Bionics among others.
| Metrics | Details | |
| CAGR | 9.3% | |
| Market Size Available for Years | 2022-2031 | |
| Estimation Forecast Period | 2024-2031 | |
| Revenue Units | Value (US$ Mn) | |
| Segments Covered | Type | Artificial Tissues, Artificial Organs |
| Material | Plastics, Metals, Collagen, Gelatin, Fibrin, Polysaccharides, Synthetic polymers, Others | |
| Fixation Type | Temporary, Permanent | |
| Technology | Mechanical Bionics, Electronic Bionics | |
| End-User | Hospitals, Specialty Clinics, Academic & Research Institutes | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa | |
Key Developments
• In October 2023, Edwards received the CE [Conformité Européenne] mark for the valve for mitral replacement surgeries. It was approved by the US Food and Drug Administration (FDA) in March 2022.
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The global artificial organs and bionics market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
